Clinical trial
An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
NCT06501976 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 31, 2025
- Completion date
- June 30, 2027
- Enrollment
- 9 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.